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Abstract: Schizophrenia is a chronic mental disorder generally treated with antipsychotic 
medication. However, non-adherence and partial adherence to antipsychotic medication treat-
ment is common and long-acting injectable “depot” preparations of antipsychotic medications 
have been used as an alternative to oral medication therapy for patients for whom adherence 
is a clinically significant problem, as well as for the sake of convenience and in response to 
patient preference. Olanzapine long-acting injection (OLAI) is a new treatment option and 
has been approved by several regulatory agencies for the treatment of schizophrenia. OLAI 
is a crystalline salt formulation of olanzapine and pamoic acid. Efficacy was established in 
2 double-blind randomized clinical trials of OLAI for the treatment of acute schizophrenia and 
for the maintenance of response. The therapeutic OLAI dosages are 150 mg q2 weeks, 210 mg 
q2 weeks, 300 mg q2 weeks or q4 weeks, and 405 mg q4 weeks, administered by deep intra-
muscular gluteal injection with a 19-gauge needle. Injection volume ranges from 1 to 2.7 mL. 
OLAI has essentially the same general tolerability as that of oral olanzapine; however with the 
depot there is the additional risk of a post-injection delirium sedation syndrome occurring at 
a rate of 0.07% of injections, requiring a risk management plan that includes observing the 
patient for 3 hours post injection.
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Introduction
Schizophrenia is a chronic mental disorder generally treated with antipsychotic 
medication. However, non-adherence and partial adherence to antipsychotic medication 
treatment is common and has been observed in about half or more of all patients with 
schizophrenia.1–3 It is estimated that about 75% of patients with schizophrenia become 
nonadherent within 2 years of hospital discharge.4 Non-adherence elevates the risk for 
relapse and re-hospitalization,5–7 inadequate treatment response,8 aggressive behavior,9 
suicide,10 and substance use.11 One approach to the problem of non-adherence is the use 
of long-acting injectable “depot” formulations of antipsychotic medication instead of, 
or in addition to, oral preparations. In addition, depot injections can be considerably 
more convenient for the patient and caregiver, and may be preferred over oral options 
by all the parties concerned.
The purpose of this review is to summarize key issues related to non-adherence and 
its management and to introduce information on a new medication option – olanzapine 
long-acting injection (OLAI) – together with data on patient-focused perspectives and 
OLAI’s potential place in the treatment of schizophrenia. Information on OLAI was Patient Preference and Adherence 2009:3 346
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obtained primarily from a prior review12 and information 
provided to the US Food and Drug Administration (FDA).13
Factors related to non-adherence
Non-adherence can be due to many different reasons. 
These include illness-related factors such as substance 
use comorbidity,1,14,15 symptom severity,1 poor insight into 
mental illness at discharge,16 impaired memory, and possibly 
hostility.8 In addition, patient-related factors can include a 
history of medication non-adherence for other disorders. 
There may also be extant several system factors such as medi-
cation availability on a formulary, access to a “depot clinic,” 
or treatment cost. Important to consider are also treatment-
related factors such as regimen complexity,17 side-effects or 
tolerability,18 or inefficacy of treatment.18,19 Weight gain, extra-
pyramidal symptoms such as stiffness, tremor, and akathisia, 
and associated dysphoria, as well as sexual dysfunction are the 
common side-effects of antipsychotics that patients may not 
tolerate and that thus result in non-adherence. The availability 
of second-generation antipsychotics, although better toler-
ated in terms of extrapyramidal symptoms, has led to only a 
small improvement in adherence rates.20
Unrecognized nonadherence can lead to the faulty impres-
sion that a medication regimen is ineffective. This can lead 
to unnecessary changes in medication,21 increases in drug 
dose,21,22 concomitant medications,21 and the inaccurate 
categorization of patients as being treatment resistant rather 
than non-adherent.21
Addressing and managing non-
adherence: non-pharmacological 
techniques
Treatment adherence can be improved by taking a psycho-
social and psychoeducational approach and exploring with 
the patients and their families their beliefs about the illness 
and its treatment, their expectations, explaining the treat-
ment and its effects, asking about the patients’ preferences, 
and making treatment decisions and recommendations in 
collaboration with the patients and families.23,24 Interview 
style is important in fostering a therapeutic alliance.25–27 The 
strength of a therapeutic alliance is predictive of adherence 
and better outcomes.28 Cognitive behavioral therapy may 
also be beneficial in improving adherence to antipsychotic 
medication among patients with schizophrenia.29,30 Cognitive 
adaptation training, a psychosocial treatment that uses 
environmental supports, can also improve adherence and 
functional outcomes.31 The individual patient’s circumstances 
and preferences should be considered when determining 
the appropriate general clinical approach and intervention 
strategy, with the proviso that “when considering adherence 
attitudes, patient belief is always reality”.27
Addressing and managing non-
adherence: depot antipsychotics
Depot antipsychotics do offer guaranteed delivery of a 
medication over an extended period of time. Covert non-
adherence, as seen with “cheeking” of oral medication, is 
not possible with an injection, and for many years has been 
thought to lead to greater effectiveness32 and reduced risk 
of relapse.33 An “early-warning” system is in place when a 
patient fails to show up for his or her scheduled injection, 
allowing case management staff to intervene expeditiously 
before further problems ensue. In the inpatient setting, using 
a q2 week or monthly medication administration schedule 
can save staff time and avoid daily medication administra-
tion struggles. Although the acquisition cost of newer depot 
medication products can be relatively high, these costs may 
be small when compared with the time saved by staff (when 
administering medication biweekly or monthly rather than 
up to 4 times per day) and by shortening hospital stays and 
improving patient outcomes. During the important inpatient 
to outpatient transition period, long-acting injectable 
antipsychotics may be advantageous in getting patients to 
attend outpatient clinic programs.4
In the US, depot neuroleptics have been in use since 1963, 
when fluphenazine enanthate was approved for marketing. 
Fluphenazine decanoate became available soon after-
ward, followed by haloperidol decanoate in 1986 (1982 in 
the UK). Several other first-generation antipsychotic depot 
formulations are available outside the United States. Up to 
very recently there has been only one second-generation 
antipsychotic available in a depot formulation – risperidone 
microspheres, available since 2003.34,35 In August 2009 
paliperidone palmitate, whose active moiety is the 9-OH 
metabolite of risperidone, received FDA approval in 2009.36
Olanzapine long-acting injection
OLAI is a crystalline salt formulation of olanzapine and 
pamoic acid that can be administered every 2 or 4 weeks.12,13 
The FDA is currently evaluating OLAI which was given a 
positive opinion by the European Medicines Agency37 and 
has been commercialized in Australia and New Zealand.38 
Oral olanzapine, available since 1996, is an efficacious39–42 
and effective18,43 antipsychotic. Olanzapine is also available Patient Preference and Adherence 2009:3 347
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in a rapid-acting (non-depot) intramuscular formulation 
specifically for the treatment of agitation.44 Similar to most 
other second-generation antipsychotics, olanzapine has a 
favorable profile in terms of extra-pyramidal side-effects but 
olanzapine can be associated with substantial weight gain and 
the development of hyperlipidemia, as well as hyperglycemia.45 
Other potential adverse effects include orthostatic hypoten-
sion, syncope, sedation, and somnolence.46
Formulation, pharmacology, 
and pharmacokinetics
OLAI is composed of micron-sized crystals suspended in 
water. Upon intramuscular injection, OLAI slowly dissociates 
over a period of several weeks into the separate molecular 
entities of olanzapine (base) and pamoic acid, with both 
components entering the bloodstream. Plasma concentrations 
remain quantifiable for several months after the last OLAI 
injection.38 The half-life of OLAI is 30 days compared to 
30 hours for oral olanzapine,38 thus achieving steady state 
takes several months. The elimination phase is complete 
approximately 6 to 8 months after the last injection.38
Efficacy
Two randomized controlled pivotal studies are extant. One 
study tested OLAI for the acute treatment of schizophrenia,13,47 
and the second focused on the maintenance of antipsychotic 
response.13 Six open-label studies were also conducted.13
The acute study enrolled 404 acutely ill patients with 
schizophrenia13,47 who were randomized to receive double-
blind OLAI 210 mg q2 weeks, 300 mg q2 weeks, or 405 mg 
q4 weeks, or placebo, without any oral antipsychotic supple-
mentation, for up to 8 weeks. The primary outcome measure 
was change in the Positive and Negative Syndrome Scale 
(PANSS) total score and this change was significantly greater 
for all olanzapine doses tested relative to placebo. Acute 
efficacy was established by demonstrating separation from 
placebo as early as 3 days (the first time point where the 
PANSS was measured after starting double-blinded treatment) 
for the 300 mg q2 weeks and 405 mg q4 weeks treatment 
arms, and as early as 7 days for the subjects receiving 210 mg 
q2 weeks. Table 1 summarizes several of the clinically 
relevant categorical outcomes, together with the effect size 
measure of number needed to treat (NNT).48
A 24-week maintenance study enrolled 1205 outpatients 
and although the study was randomized and double-blind, 
it was not placebo-controlled.13 Patients were eligible to be 
randomized to OLAI or oral olanzapine provided they had 
maintained stability on open-label oral olanzapine (10, 15, 
or 20 mg/day) for 4 to 8 weeks. There were 5 treatment 
groups: OLAI 405 mg q4 weeks, 300 mg q2 weeks, 150 mg 
q2 weeks, 45 mg q4 weeks, or 10, 15, or 20 mg/day oral 
olanzapine (whichever oral dose they had been stabilized on 
prior to randomization). The low-dose treatment arm of OLAI 
(45 mg q4 weeks) was included to serve as a comparator for 
the superiority analysis to therapeutic doses of OLAI, and 
can be considered as a placebo-equivalent. No supplemen-
tation with oral antipsychotic therapy was permitted after 
randomization. At randomization, the mean PANSS total 
score was 56, indicating a low level of psychopathology. The 
primary outcome studied was time to exacerbation of illness, 
defined by worsening of positive symptoms (conceptual 
disorganization, hallucinatory behavior, suspiciousness, 
unusual thought content) since randomization, or hospitaliza-
tion due to worsening of positive psychotic symptoms. Each 
of the therapeutic OLAI doses was statistically superior to the 
45 mg q4 weeks dose with respect to time to exacerbation of 
symptoms. In a non-inferiority analysis, subjects receiving 
OLAI 150 or 300 mg q2 week had a similar non-exacerbation 
rate compared to the oral olanzapine group (90% versus 93% 
for depot and oral respectively) and was thus was non-inferior 
to the oral olanzapine treatment group. In addition, OLAI 
405 mg q4 weeks was non-inferior to the oral olanzapine 
and the pooled q2 weeks depot dosing groups. Categorical 
outcomes are described in Table 2.
Safety
The general safety and tolerability profile for OLAI is similar 
to that for oral olanzapine.45 However, during the OLAI 
clinical trial program a small number of adverse events 
termed post-injection delirium/sedation syndrome (PDSS) 
was observed in a small proportion of patients.13 PDSS 
appears to be related to potential intravascular injection of a 
portion of the OLAI dose.13 As of May 30, 2008, a total of 
29 PDSS events have been identified in 28 patients during 
OLAI clinical trials. Based on more than 40,000 OLAI injec-
tions given to 2054 patients in clinical trials through May 30, 
2008, PDSS events have occurred in approximately 0.07% 
of injections, or 1.4% of patients.49 Signs and symptoms in 
PDSS events appear consistent with olanzapine overdose and 
include dizziness, confusion, disorientation, slurred speech, 
altered gait, weakness, and a reduced level of consciousness 
ranging from mild sedation to coma.49 When plasma levels 
for olanzapine were available immediately after a PDSS 
event, a much higher olanzapine plasma concentration was 
observed than would have been expected.13 Onset of signs Patient Preference and Adherence 2009:3 348
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and symptoms may be between 5 minutes and 5 hours 
(1 case occurred 3 to 5 hours after injection; median time 
to onset is 20 minutes; approximately 80% of patients had 
onset 60 minutes). None of the PDSS events involved 
sudden onset of profound sedation or incapacitation; instead, 
all began with milder symptoms, which progressed to more 
severe symptoms in some events. In general, the later the 
onset of symptoms, the slower their progression. All patients 
fully recovered from the events within 24 to 72 hours after 
injection, and the majority continued to receive further injec-
tions of OLAI.49 One patient experienced two PDSS events. 
He is the only patient to have experienced the event more 
than once, and these events occurred approximately 6 months 
apart.13 On average, PDSS events occurred after the patient 
had received several months of injections (median number of 
injections was 17) and ranged in occurrence from 1 event at 
the first injection to 1 event at the 40th injection. The mean 
number of days (from starting treatment with OLAI) to an 
event was 278 days.13 The cumulative risk of a PDSS event 
occurring in an individual is estimated to be 0.7% to 1.2% 
after 1 year, 2.1% to 2.9% after 5 years, and 3.8% to 4.8% 
after 20 years of treatment.13 Potential risk factors include a 
Table 1 OLAi acute schizophrenia study
N (randomized) 404
Length 8 weeks
Arms, completion rate,
NNT for completion vs placebo and 95%  
confidence interval
Placebo (N = 98), 57%
OLAi 210 mg q2 weeks (N = 106), 68%, NNT 10 (ns)
OLAi 300 mg q2 weeks (N = 100), 67%, NNT 11 (ns)
OLAi 405 mg q4 weeks (N = 100), 72%, NNT 7 (4, 60)
Timing of improvement over placebo OLAi 210 mg q2 weeks – Day 7
Olanzapine 300 mg q2 weeks – Day 3
Olanzapine 405 mg q4 weeks – Day 3
response by at least 40% improvement in the 
PANSS total score from baseline to endpoint, 
NNT vs placebo and 95% confidence interval
Placebo, 20.4%
OLAi 210 mg q2 weeks, 47.2%, NNT 4 (3, 7)
OLAi 300 mg q2 weeks, 48.0%, NNT 4 (3, 7)
OLAi 405 mg q4 weeks, 40.0%, NNT 6 (4, 15)
Treatment-related adverse events leading to 
discontinuation, NNT vs placebo and 95% 
confidence interval
Placebo, 5.1%
OLAi 210 mg q2 weeks, 2.8%, NNT 44 (ns)
OLAi 300 mg q2 weeks, 6.0%, NNT -112 (ns)
OLAi 405 mg q4 weeks, 4.0%, NNT 91 (ns)
weight gain of at least 7% of baseline, NNT vs   
placebo and 95% confidence interval
Placebo, 12.4%
OLAi 210 mg q2 weeks, 23.6%, NNT 9 (5, 102)
OLAi 300 mg q2 weeks, 35.4%, NNT 5 (3, 9)
OLAi 405 mg q4 weeks, 27.0%, NNT 7 (4, 26)
Changes in plasma cholesterol Significant group differences were observed for mean baseline-to-end point changes in fasting 
total cholesterol (210 mg q2 weeks, 8.2 mg/dL; 300 mg q2 weeks, 5.5 mg/dL; 405 mg q4 weeks, 
10.4 mg/dL vs placebo, –7.0 mg/dL)
Changes in plasma triglycerides Significant group differences were observed for mean baseline-to-end point changes in fasting 
triglycerides (OLAi 210 mg q2 weeks, 26.3 mg/dL; 405 mg q4 weeks, 30.3 mg/dL groups vs placebo, 
–9.4 mg/dL); a significantly greater percentage of patients in the OLAI 210 mg q2 weeks (12.8%) 
and 300 mg q2 weeks (14.3%) groups experienced changes in triglyceride levels from 150 mg/dL 
to 200–500 mg/dL vs placebo (3.4%), with a NNT of 11 and 10, respectively
Changes in plasma glucose Mean baseline-to-end point changes in fasting glucose did not differ significantly between treatment 
groups
extra-pyramidal adverse events extrapyramidal symptoms were low at baseline for all treatment groups, and none of the group 
differences in baseline-to-end point changes on the Simpson-Angus, Barnes Akathisia or Abnormal 
involuntary Movement scales were clinically meaningful
Changes in plasma prolactin   Not reported
Notes: ns – NNT not significant (95% confidence interval includes ∞).
Adapted with permission from   Table 2 in Citrome L. Olanzapine pamoate: a stick in time?   A review of the efficacy and safety profile of a new depot formulation of a second-
generation antipsychotic. Int J Clin Pract. 2009;63(1):140–150.12 Copyright © 2009.
Abbreviations: OLAi, olanzapine long-acting injection; PANSS, Positive and Negative Syndrome Scale; NNT, number needed to treat.Patient Preference and Adherence 2009:3 349
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higher dose (related to an increased injection volume), greater 
age, and low body mass index (BMI), however risk remains 
low even for patients with these specific risk factors.13 For 
example, a logistic regression model predicted that a 50-year-
old patient with a BMI of 22 kg/m2 who received a 405 mg 
injection would have a probability of 0.0032 for experiencing 
a PDSS event.13
One possible explanation for why PDSS can occur is that 
OLAI is more soluble in blood or plasma than in muscle.13 
Partial injection into vasculature, vessel injury associated with 
the intramuscular injection such as with a nick or puncture of 
the blood vessel, or substantial bleeding at the injection site 
may result in a rapid release of a portion of the OLAI dose.
Because of PDSS, risk management plans have been put 
into place.49,50 Elements of the plan adopted by the European 
Medicines Agency are outlined in Table 3. The central feature 
is that after each injection, patients should be observed in a 
healthcare facility by appropriately qualified personnel for 
Table 2 OLAi maintenance of antipsychotic response in schizophrenia study
N (randomized) 1065
Length 24 weeks
Arms, completion rate, NNT for completion vs   
OLAI 45 mg q4 weeks and 95% confidence 
interval
OLAi 45 mg q4 weeksa (N = 144), 52.8%
OLAi 150 mg q2 weeks (N = 140), 64.3%, NNT 9 (5, 825)
OLAi 300 mg q2 weeks (N = 141) , 75.9%, NNT 5 (3, 9)
OLAi 405 mg q4 weeks (N = 318) , 70.0%, NNT 6 (4, 14)
Olanzapine oral 10, 15, or 20 mg/day (N = 322) , 80.1%, NNT 4 (3, 6)
Free of exacerbation at 24-weeks, NNT vs 
OLAI 45 mg q4 weeks and 95% confidence 
interval
OLAi 45 mg q4 weeks, 69%
OLAi 150 mg q2 weeks, 84%, NNT 7 (4, 18)
OLAi 300 mg q2 weeks, 95%, NNT 4 (3, 6)
OLAi 405 mg q4 weeks, 90%, NNT 5 (4, 8)
Olanzapine oral 10, 15, or 20 mg/day, 93%, NNT 5 (4, 7)
Treatment-related adverse events leading to 
discontinuation, NNT vs OLAi 45 mg q4 weeks 
and 95% confidence interval
OLAi 45 mg q4 weeks, 4.2%
OLAi 150 mg q2 weeks, 5.0%, NNT –125 (ns)
OLAi 300 mg q2 weeks, 2.8%, NNT 76 (ns)
OLAi 405 mg q4 weeks, 3.1%, NNT 98 (ns)
Olanzapine oral 10, 15, or 20 mg/day, 2.5%, NNT 60 (ns)
weight gain of at least 7% of baseline, NNT 
vs OLAI 45 mg q4 weeks and 95% confidence 
interval
OLAi 45 mg q4 weeks, 8.3%
OLAi 150 mg q2 weeks, 16.4%, NNT 13 (7, 205)
OLAi 300 mg q2 weeks, 20.7%, NNT 9 (5, 24)
OLAi 405 mg q4 weeks, 15.2%, NNT 15 (8, 130)
Olanzapine oral 10, 15, or 20 mg/day, 21.4%, NNT 8 (6, 15)
Changes in plasma cholesterol Increases in fasting total cholesterol and fasting LDL cholesterol were significantly greater for 
the therapeutic OLAI doses relative to the 45 mg q4 weeks dose; No significant between group 
differences were observed for baseline-to-endpoint changes in HDL cholesterol levels;   Analyses 
of categorical changes in cholesterol at any time revealed no significant group differences
Changes in plasma triglycerides No significant between group differences were observed for baseline-to-endpoint changes in 
fasting triglyceride levels; analyses of categorical changes in fasting triglycerides evidenced a 
greater proportion of patients shifting from 150 mg/dL to high in the OLAi 300 mg q2 weeks 
group (26%) relative to the 405 mg q4 weeks (9%), 150 mg q2 weeks (5%) and 45 mg q4 weeks 
(4%) groups (NNT of 6, 5, and 5, respectively)
Changes in plasma glucose No significant between-group differences were observed for baseline-to-endpoint changes in 
fasting glucose; analyses of categorical changes in fasting glucose at any time revealed no significant 
group differences
extra-pyramidal adverse events extrapyramidal symptoms were low at baseline and throughout the study for all treatment 
groups; no statistically significant differences were observed between treatment groups with 
respect to changes on the Simpson-Angus, Barnes Akathisia or Abnormal involuntary Movement 
scales; no statistically significant differences in treatment-emergent extrapyramidal symptoms
Changes in plasma prolactin Increases in prolactin were significantly greater for the therapeutic OLAI doses relative to the 
45 mg q4 weeks dose; as dose increased, mean changes in prolactin were greater
Notes: ns – NNT not significant (95% confidence interval includes ∞); aOLAi 45 mg q4 weeks can be considered as a placebo-equivalent.
Adapted with permission from   Table 2 in Citrome L. Olanzapine pamoate: a stick in time?   A review of the efficacy and safety profile of a new depot formulation of a second-
generation antipsychotic. Int J Clin Pract. 2009;63(1):140–150.12 Copyright © 2009.
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; OLAi, olanzapine long-acting injection; NNT, number needed to treat.Patient Preference and Adherence 2009:3 350
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Table 3 risk minimization plan
Appropriate labeling
Provide adequate labeling to prescribers and patients about clinically relevant safety observations, including those related to post-injection syndrome.
Specific information and instructions to be included in the label will provide:
  •    Description of post-injection syndrome proposed as a warning in the summary of product characteristics (SPC)
  •    Description of reconstitution and proper administration technique
  •    recommendation for a 3-hour on-site observation period post injection
  •    recommendation that prior to giving the injection, the health care professional should determine that the patient will not travel alone to their 
destination
  •    recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be 
vigilant for signs and symptoms of a post-injection syndrome event, and should be able to obtain assistance if needed
  •    Description of the most common symptoms reported with olanzapine overdose that represent the clinical manifestation in post-injection 
syndrome events
  •    recommendation for appropriate monitoring until the event resolves if an event should occur
Risk-minimization training and communication
  •    Product introduction Letter sent to all psychiatrists and other targeted prescribers of depots
  •    Provide targeted health care professional education about proper administration techniques, the risk of accidental intravascular injection with 
intramuscularly injected drugs, as well as the clinical presentation and management of patients reporting post-injection syndrome events
  •    Provide patients with a card containing a description of the most common symptoms associated with the post-injection syndrome together with 
appropriate contact details and advice
  •   Assess effectiveness of risk minimization measures (that is, annual assessment of risk minimization training program [duration will be based on the 
assessment of these data and in agreement with the Committee for Medicinal Products for Human Use], an evaluation of adherence to SPC/
guidelines by prescribers, and implementation of an observational study)
Education program for doctors, nurses, and pharmacists – specifics
  •    Description of post-injection syndrome
        education about the two intramuscular formulations of olanzapine, including packaging differences
        Description of reconstitution and proper administration technique
        recommendation for a 3-hour on-site observation period post injection
        recommendation that prior to giving the injection, the health care professional should determine that the patient will not travel alone to their 
destination
        recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should 
be vigilant for signs and symptoms of a post-injection syndrome event, and should be able to obtain assistance if needed
        Description of the most common symptoms reported with olanzapine overdose that represent the clinical manifestation in post-injection 
syndrome events
        recommendation for appropriate monitoring until the event resolves if an event should occur
  •    recommendations for monitoring of patients for glucose, lipids, and weight
        Promote awareness of appropriate metabolic monitoring by distributing utilized published antipsychotic guidelines
Contents of patient card distributed to all patients
  •    Description of post-injection syndrome
  •    recommendation for a 3-hour on-site observation period post injection
  •    recommendation that prior to giving the injection, the health care professional should determine that the patient will not travel alone to their 
destination
  •    recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be 
vigilant for signs and symptoms of a post-injection syndrome event, and should be able to obtain assistance if needed
  •    Description of the most common symptoms reported with olanzapine overdose that represent the clinical manifestation in post-injection 
syndrome events
  •    recommendation for appropriate monitoring until the event resolves if an event should occur
aSources: european Medicines Agency.   Assessment report for Zypadhera, 2008. http://www.emea.europa.eu/humandocs/PDFs/ePAr/Zypadhera/H-890-en6.pdf. Accessed 
September 2009;49 european Medicines    Agency.    Annex: Conditions or restrictions with regard to the Safe and effective Use of Medicinal Product to be implemented by the 
Member States, 2008. http://ec.europa.eu/enterprise/pharmaceuticals/register/2008/2008111950550/anx_50550_en.pdf.    Accessed September 2009.50Patient Preference and Adherence 2009:3 351
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at least 3 hours and that they should not drive or operate 
machinery for the remainder of the day of the injection. 
In New Zealand, product labeling further specifies that 
OLAI be administered in a healthcare facility with access to 
emergency services for management of olanzapine overdose 
and that active monitoring for alertness take place every 
30 minutes during the 3 hour post-injection observation 
period.38
In addition to routine post-marketing surveillance, 
OLAI’s manufacturer plans to undertake a multinational 
Phase IV, non-interventional, prospective cohort study, 
focusing on PDSS risk in approximately 5000 patients. The 
study will estimate the crude incidence of PDSS events over 
a 2-year period in patients treated with OLAI in clinical 
practice and identify potential risk factors associated with 
the occurrence of PDSS events and further characterize the 
clinical presentation of these events in a naturalistic setting. 
It will also provide the opportunity to compare the incidence, 
severity, and outcomes of PDSS events in clinical trials 
with normal clinical practice to determine if there are any 
clinically meaningful differences.13
Dosing and administration
New information is available on the optimal dose for oral 
olanzapine that may have implications on what dose of 
OLAI would be best. The optimal dose of oral olanzapine 
for most patients is likely 10 to 20 mg/day, as evidenced by 
a fixed-dose randomized clinical trial comparing olanzapine 
10 mg/day, 20 mg/day, and 40 mg/day.51 Over the 8 weeks of 
the study, non-treatment-resistant patients with schizophre-
nia or schizoaffective disorder responded to all 3 doses of 
olanzapine, without a statistically significant dose-response 
relationship, suggesting that for many patients with schizo-
phrenia or schizoaffective disorder, particularly those who 
are mildly or moderately ill, 10 mg/day should be the initial 
dose of choice. In terms of tolerability, the 40 mg/day group 
demonstrated greater weight gain and change in plasma 
prolactin than the 10 mg/day group.51 See Citrome and 
Kantrowitz52 for a review of dose response for olanzapine.
The therapeutic OLAI dosages are 150 mg q2 weeks, 
210 mg q2 weeks, 300 mg q2 weeks or q4 weeks, and 
405 mg q4 weeks. Three vial strengths are available 
(210 mg, 300 mg, 405 mg) and are reconstituted to a fixed 
concentration of 150 mg/mL, for a volume of injection of 
1 to 2.7 mL, for deep intramuscular gluteal injection with 
a 19-gauge needle.38 Systemic olanzapine exposures with 
OLAI at these doses are at levels that are comparable to those 
associated with once-daily oral administration of olanzapine 
within the range of 10 to 20 mg/day. Table 4 provides the 
dose correspondence between OLAI and oral olanzapine 
at steady state.13 Based on analyses of the pivotal 24-week 
maintenance study at 2 months, in order to minimize the risk 
for exacerbation at the start of treatment, the recommended 
start dose of OLAI for the first 2 months of  treatment 
(in effect a “loading dose”) differs from the maintenance 
dose, as shown in Table 5. Although OLAI has not been 
systematically studied in patients 65 years and over, product 
labeling in New Zealand suggests a low starting dose of 
150 mg q4 weeks if used in this population.38 As noted in a 
commentary, a further complicating factor is that each OLAI 
vial strength requires a different volume of the supplied 
diluent.53 There is more diluent in the vial than is needed to 
reconstitute. Thus, staff administering OLAI will need to be 
vigilant to ensure correct dosing.
Patient-focused perspectives
Patient-focused perspectives such as quality of life, patient 
satisfaction, and acceptability are important. Patient per-
ception of mediation benefit has been shown to be a strong 
predictor of treatment duration.54
The need for outcome measures other than those for psy-
chopathology has been appreciated for many years. Patients 
with schizophrenia do not necessarily see their condition 
the same way as their treating clinician.55 Among 53 chronic 
out-patients with schizophrenia on maintenance treatment 
with depot neuroleptics, 60% of the patients viewed depot 
medication positively. Insight was limited: only 49% of 
patients thought they had a psychotic illness, and there was 
no correlation between the patients’ own evaluation of the 
severity of their illness and their score on the PANSS or the 
treating physician’s evaluation. Mental side-effects such as 
subjective akathisia, dysphoria, and emotional indifference 
Table 4 Dose correspondence between OLAi and oral olanzapine 
at steady state
Dose of oral  
olanzapine 
 
Corresponding  
dose of OLAI  
administered  
q2 weeks
Corresponding  
dose of OLAI  
administered  
q4 weeks
10 mg/day 150 mg 300 mg
15 mg/day 210 mg 405 mg
20 mg/day 300 mg NA
Source:   Table 3.1 in eli Lilly and Company.   Zyprexa Olanzapine Pamoate (OP) Depot, 
Psychopharmacological Drugs Advisory Committee Briefing Document, 3 January 
2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-03-Lilly.pdf. 
Accessed September 2009.13
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were most often observed by the patients, while hypokinesia 
and hyperkinesia were least noticed by them, but most often 
observed by the physician. Quality of life did not correlate 
with either side-effect score or PANSS score.55
Limited information is available about satisfaction and 
attitudes towards OLAI. In one of the open-label clinical 
trials (HGKB),13 the Patient Satisfaction with Medication 
Questionnaire–Modified (PSMQ) was administered. The 
PSMQ-Modified as such is unpublished but the original 
scale has been described56 and consists of 10 questions, 
including a likert-type question on satisfaction with current 
medication and another on perception of frequency of 
side-effects with the current medication. There are also 
narrative questions such as “Overall do you prefer your 
current medication or your previous medication?” and 
“Has any caretaker made any comments on any differences 
between you being on your current medication and previous 
medications?” The majority of patients (70.6%) reported 
satisfaction with OLAI; 69% reported that they preferred 
OLAI over previous oral medications; and 71.6% reported 
experiencing less impact from side-effects on OLAI 
compared with previous oral medications.13 Of interest, 
16 of the 24 patients experiencing a PDSS event weighed the 
benefits against the risks of OLAI treatment and continued 
to receive OLAI.13
Place in therapy
Long-acting injectable depot preparations of antipsychotics 
offer a guaranteed delivery system that eliminates the 
possibility of covert non-adherence. By not coming to the 
clinic for the next injection, non-adherence becomes readily 
identifiable and further outreach can be done expeditiously. 
By providing a steady amount of a therapeutic dose of an 
antipsychotic, maintenance of response is enhanced and 
relapse can be prevented or delayed. However, despite these 
advantages, the use of depot antipsychotics faces several 
obstacles among psychiatrists, nurses, and patients. These 
will be required to be addressed in order for OLAI to be 
used successfully.
There is a belief among psychiatrists that their patients are 
sufficiently compliant with oral antipsychotic medication.57 
Moreover there are concerns that first-generation depots 
ought to be avoided because of the risk for extrapyramidal 
side-effects, and that second-generation long-acting 
injectable drugs are expensive.57 In a survey of psychiatrists 
in the UK,58 40% believed that depots are old fashioned 
and 48% thought they were stigmatizing. Although almost 
all (91%) thought that depots are as efficacious as oral 
medication, there was a belief among 69% that depots 
would be less acceptable to patients. However, respondents 
did endorse advantages: 81% considered depots being 
able to enhance patient compliance; 94% endorsed the 
belief that depots prevent relapse. The authors note that 
psychiatrists would be persuaded to prescribe depots if 
they were associated with fewer side-effects, in patients 
where compliance is an issue, and if second-generation 
antipsychotics were available, presumably because they 
would have a lower incidence of side-effects.
Nursing obstacles have also been identified.59,60 Negative 
views include the thought that depots are old fashioned, 
stigmatizing, and the perception that most patients always 
prefer to have oral medication and that force is sometimes 
required when administering a depot. However, familiarity 
with depots and knowledge of side-effects were positively 
associated with favorable attitudes.60
Although depot antipsychotics can be perceived as 
more coercive than oral medications by some patients61 it 
appears that many patients would be willing to take depot 
antipsychotics if they were made available.62 Patient pref-
erences for a depot formulation versus on oral tablet are 
likely related to current and past experiences with depot.62,63 
Thus, when a new depot formulation becomes available, 
differences from past injectables needs to be emphasized 
when offering the new choice.
OLAI was demonstrated to be efficacious in acutely 
ill patients,47 and in the maintenance of response.13 OLAI 
shares the same general safety profile as oral olanzapine. 
This includes both favorable aspects (low potential for 
extrapyramidal effects) and an unfavorable metabolic profile 
(high potential for weight gain, lipid abnormalities, and 
insulin resistance).45 A risk unique to the depot formulation 
of olanzapine is that of PDSS, requiring the implementation 
Table 5 recommended dose schedule for OLAi relative to oral 
olanzapine: start dose (2 months) and maintenance dosea
Target oral  
olanzapine  
dose
Recommended  
starting dose  
of OLAI
Maintenance dose 
after 2 months 
of OLAI
10 mg/day 210 mg q2 weeks or  
405 mg q4 weeks
150 mg q2 weeks or 
300 mg q4 weeks
15 mg/day 300 mg q2 weeks 210 mg q2 weeks or 
405 mg q4 weeks
20 mg/day 300 mg q2 weeks 300 mg q2 weeks
Source:    Table 3.1 in eli Lilly and Company.  Zyprexa Olanzapine Pamoate (OP) Depot, 
Psychopharmacological Drugs Advisory Committee Briefing Document, 3 January 
2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-03-Lilly.pdf. 
Accessed September 2009.13
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of a risk management plan. This requirement may limit 
access to OLAI.
When assessing potential benefit and risk, OLAI may be 
best suited for patients who have a clear history of response to 
olanzapine and for whom a depot may enhance their ability to 
remain adherent. Alternatives include first-generation depot 
antipsychotics, risperidone microspheres, and paliperidone 
palmitate. Studies directly comparing these options would 
be desirable to discern whether or not there are any differ-
ences in terms of prevention of exacerbation, relapse and/or 
hospitalizations among the different choices.
Practical considerations for the three commercially 
available second-generation antipsychotics are summa-
rized in Table 6.38,64,65 Needle gauge is largest for OLAI 
and smallest for paliperidone palmitate. The latter agent is 
unique in that it comes in prefilled syringes. In contrast to 
risperidone microspheres, OLAI and paliperidone palmitate 
do not require refrigeration, can be given monthly, and do 
not require oral supplementation when initiating therapy. 
Both OLAI and paliperidone palmitate require different 
doses for initiation and for maintenance. OLAI must be 
administered in the gluteal muscle but risperidone micro-
spheres and paliperidone palmitate may also be administered 
in the deltoid muscle. OLAI is unique in requiring a 3-hour 
post-injection monitoring period.
Conclusions
Depot antipsychotics are an important treatment option for 
patients with schizophrenia who are nonadherent or partially 
adherent to their medication treatment. They also represent 
a convenient option for patients who prefer a monthly injec-
tion over a more complicated regimen. Up to now, choices 
for a second-generation depot antipsychotic have been 
limited. Newly available is OLAI. Treatment with OLAI 
Table 6 Characteristics of the three commercially available depot second-generation antipsychotics
Characteristic OLAIa Risperidone microspheresb Paliperidone palmitatec
Year commercialized 2009 2003 2009
Active moiety Olanzapine risperidone and 9-OH-risperidone 9-OH-risperidone
Approved indications Acute and maintenance 
treatment of schizophrenia 
in adults
Schizophrenia; bipolar i disorder 
maintenance treatment 
(as monotherapy or as adjunctive 
therapy to lithium or valproate)
Acute and maintenance treatment 
of schizophrenia in adults
Dosage forms/strengths vial kits of 210, 300, 
and 405 mg
vial kits of 12.5, 25, 37.5, and 50 mg Prefilled syringes of 39, 78, 117, 
156, and 234 mg
Approved injection sites Gluteal muscle Deltoid or gluteal muscle Deltoid or gluteal muscle
Needle gauge 19 G 21 G (deltoid) or 20 G (gluteal) 22 G (deltoid, patient 
weight 90 kg) or 23 G (deltoid,  
patient weight 90 kg) or 
22 G (gluteal)
injection frequency q2 weeks or q4 weeks q2 weeks q4 weeks
Starting dose Can vary (see Table 5) 25 mg 234 mg on treatment day 1 
and 156 mg 1 week later, both 
administered in the deltoid muscle
Maintenance dose Can vary (see Table 5) 25 mg (maximum recommended 
dose 50 mg)
117 mg (recommended range 
39–234 mg)
requirement for oral 
supplementation
No Yes (21 days) No
requirement for refrigeration No Yes No
requirement for observation  
post injection
Yes (3 hours)  No  No 
aEli Lilly and Company (NZ) Limited. Zyprexa Relprevv, Olanzapine (as pamoate monohydrate) depot injection. Data Sheet. July 2009.38
bJanssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Risperdal Consta (risperidone) Long-Acting Injection. Product Information. July 2009. http://www.risperdalconsta.
com/risperdalconsta/shared/pi/risperdalconsta.pdf. Accessed September 2009.64
cJanssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Invega Sustenna (paliperidone palmitate) Extended-Release Injectable Suspension. Product Information. July 
2009. http://www.invegasustenna.com/invegasustenna/shared/pi/invegasustenna.pdf. Accessed September 2009.65
Adapted with permission from  Table 5 in Citrome L. Paliperidone palmitate – review of the efficacy, safety, and cost of a new second-generation depot antipsychotic medication. 
Int J Clin Pract. in press. 2009.36 Copyright © 2009.
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210 mg q2 weeks, 405 mg q4 weeks, and 300 mg q2 weeks 
appears efficacious in acutely ill patients with schizophrenia. 
OLAI was also demonstrated to be efficacious in the 
maintenance of response with either the q2 weeks or q4 weeks 
dosing options. The general safety profile for OLAI is similar 
to that for oral olanzapine however there is a small additional 
risk of PDSS, occurring at a rate of 0.07% of injections or 
1.4% of patients. This risk requires that patients be super-
vised by health care personnel for 3 hours post injection. 
OLAI appears to be best suited for the patient who responds 
well to olanzapine but who is having difficulties remaining 
adherent to oral antipsychotic medication.
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